AMBULUNG
Ambulatory Bio-Artificial Lung
| Coordinatore | NOVALUNG GMBH
Organization address
address: IM ZUKUNFTSPARK 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 7˙416˙968 € |
| EC contributo | 5˙650˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-2 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-07-01 - 2015-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
NOVALUNG GMBH
Organization address
address: IM ZUKUNFTSPARK 1 contact info |
DE (HEILBRONN) | coordinator | 3˙435˙833.20 |
| 2 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 1˙122˙760.00 |
| 3 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 779˙940.00 |
| 4 |
UNIVERSITA DEGLI STUDI DI FIRENZE
Organization address
address: Piazza San Marco 4 contact info |
IT (Florence) | participant | 250˙000.00 |
| 5 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 61˙466.66 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide. Long-term respiratory support increases the life expectancy and the quality of life of COPD patients and decreases the cost of care. Currently available artificial lungs, such as Novalung’s iLA system, fail after ~ one month, mainly due to thrombus formation at the blood/machine interface. The size of current systems restrict patient mobility. We aim to create a wearable bioartificial lung (AmbuLung) for long-term application in an outpatient setting. The goals are to (1) miniaturise the existing iLA system, including the supporting technology and patient monitoring system; (2) cellularise the diffusion membrane with endothelial cells to decrease thrombogenicity and to increase the gas-exchange rate; and (3) evaluate the developed system in pre-clinical and clinical studies. The innovation includes (i) development of a novel alveolo-capillary gas-exchange membrane, functionalised with bioactive molecules and seeded with endothelial cells, ii) miniaturisation of mechanical and electronic device components, and (iii) novel vascular access system. For cellularisation, endothelial cells derived from FDA approved clinical grade human pluripotent stem cells will be used. Cell differentiation, scale-up, seeding, and maintenance will be performed using established automatable and scalable dynamic bioreactor technology. A mathematical model will be developed to predict and refine the function of this complex system in vitro and in vivo. AmbuLung will be evaluated in a pig model, assessing functionality, and non-thrombogenicity. The data will provide information required for potential clinical transfer. If successful, a clinical trial will be carried out on 5 COPD patients after acquisition of necessary regulatory approvals. Evaluation of efficacy of the intervention will be based on multidimensional health status grading.'
Introduzione (Teaser)
A revolutionary new artificial lung promises to significantly increase the quality of life and life expectancy of the millions of people suffering from chronic obstructive pulmonary disease (COPD).